Interleukin-10 (IL-10) polymorphic variants are linked with cytokine production and are involved in many chronic inflammatory diseases, including type 2 diabetes mellitus (T2DM). We investigated the hypothesis that IL-10 promoter polymorphisms may be associated with cytokine expressions involved in the progression of diabetic nephropathy (DN).
Study Design:
A total of 72 Taiwanese subjects were included in this study; along with a control group, patients had a diagnosis of DN lasting ≥2 years, and patients had a diagnosis of T2DM with normal renal functions lasting ≥5 years. Their IL-10 and tumor necrosis factor-α (TNF-α) genotyping and association of blood chemistry, plasma IL-10, TNF-α, and monocyte chemoattract protein-1 (MCP-1), and urinary MCP-1 were investigated.
Results:
The IL-10-(-592) genotype exhibited significant association with cytokine expressions in DN: significantly higher TNF-α and lower plasma IL-10 levels were observed in IL-10-(-592)AA, whereas a higher urine MCP-1 level was found in Taiwanese patients with the IL-10-(-592)CC genotype.
Conclusions:
IL-10-(-592) promoter polymorphisms may influence IL-10 and MCP-1 production, which may be an indicator of nephropathy risk in Taiwanese T2DM patients.
Get full access to this article
View all access options for this article.
References
1.
FreedmanBI, BowdenDW, RichSS, AppelRG. Genetic initiation of hypertensive and diabetic nephropathy. Am J Hypertens, 1998; 11:251–257.
2.
WangY, NgMC, SoWY, MaR, KoGT, TongPC, ChanJC. Association between tumour necrosis factor-alpha G-308A polymorphism and risk of nephropathy in obese Chinese type 2 diabetic patients. Nephrol Dial Transplant, 2005; 20:2733–2738.
3.
TeschGH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol, 2008; 294:F697–F701.
4.
EzzidiI, MtiraouiN, KacemM, MallatSG, MohamedMB, ChaiebM, MahjoubT, AlmawiWY. Interleukin-10-592C/A, −819C/T and −1082A/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes (T2DM) patients. Clin Endocrinol (Oxf), 2009; 70:401–407.
TegoshiH, HasegawaG, ObayashiH, NakanoK, KitagawaY, FukuiM, MatsuoS, DeguchiM, OhtaM, NishimuraM, NakamuraN, YoshikawaT. Polymorphisms of interferon-gamma gene CA-repeat and interleukin-10 promoter region (-592A/C) in Japanese type I diabetes. Hum Immunol, 2002; 63:121–128.
7.
ChangYH, HuangCN, WuCY, ShiauMY. Association of interleukin-10 A-592C and T-819C polymorphisms with type 2 diabetes mellitus. Hum Immunol, 2005; 66:1258–1263.
8.
ScarpelliD, CardelliniM, AndreozziF, LarattaE, HribalML, MariniMA, TassiV, LauroR, PerticoneF, SestiG. Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in Caucasian Italian subjects. Diabetes, 2006; 55:1529–1533.
9.
WegerM, SteinbruggerI, El-ShabrawiY, WegscheiderBJ, WegerW, RennerW, SchmutO, HaasA. Haplotype-tagging interleukin-10 promoter polymorphism is associated with reduced risk of retinal artery occlusion. Mol Vis, 2007; 13:549–552.
10.
MooreKW, de Waal MalefytR, CoffmanRL, O'GarraA. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 2001; 19:683–765.
11.
OumaC, DavenportGC, WereT, OtienoMF, HittnerJB, VululeJM, MartinsonJ, Ong'echaJM, FerrellRE, PerkinsDJ. Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production. Hum Genet, 2008; 124:515–524.
12.
BabelN, GabdrakhmanovaL, HammerMH, SchoenemannC, SkrypnikovV, PoliakN, VolkHD, ReinkeP. Predictive value of cytokine gene polymorphisms for the development of end-stage renal disease. J Nephrol, 2006; 19:802–807.
13.
TsiavouA, HatziagelakiE, ChaidaroglouA, ManginasA, KoniavitouK, DegiannisD, RaptisSA. TNF-alpha, TGF-beta1, IL-10, IL-6, gene polymorphisms in latent autoimmune diabetes of adults (LADA) and type 2 diabetes mellitus. J Clin Immunol, 2004; 24:591–599.
HernándezC, SeguraRM, FonollosaA, CarrascoE, FranciscoG, SimóR. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med, 2005; 22:719–722.
16.
NavarroJF, Mora-FernándezC. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev, 2006; 17:441–450.
17.
TarabraE, GiuntiS, BaruttaF, SalvidioG, BurtD, DeferrariG, GambinoR, VergolaD, PinachS, PerinPC, CamussiG, GrudenG. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes, 2009; 58:2109–218.
18.
WuCC, ChenJS, LuKC, ChenCC, LinSH, ChuP, SytwuHK, LinYF. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta, 2010; 411:700–704.
19.
WangQY, ChenFQ. Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in type 2 diabetes mellitus. Diabetes Res Clin Pract, 2009; 83:215–219.
20.
van ExelE, GusseklooJ, de CraenAJ, FrölichM, Bootsma-Van Der WielA, WestendorpRG. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes, 2002; 51:1088–1092.
21.
MtiraouiN, EzzidiI, KacemM, Ben Hadj MohamedM, ChaiebM, Haj JilaniAB, MahjoubT, AlmawiWY. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients. Diabetes Metab Res Rev, 2009; 25:57–63.
22.
KahramanS, YilmazR, AriciM, AltunB, ErdemY, YasavulU, TurganC. IL-10 genotype predicts serum levels of adhesion molecules, inflammation and atherosclerosis in hemodialysis patients. J Nephrol, 2006; 19:50–56.
23.
KucharzikT, LügeringN, PauelsHG, DomschkeW, StollR. IL-4, IL-10 and IL-13 down-regulate monocyte-chemoattracting protein-1 (MCP-1) production in activated intestinal epithelial cells. Clin Exp Immunol, 1998; 111:152–157.
